Human Blood and Cardiovascular Portfolio Expands at CAI
SAN DIEGO, May 16, 2016 -- Officials at Cell Applications, Inc. announce the addition of primary cells to their collection of Blood and Cardiac cells. Human Peripheral Blood Mononuclear Cells, or “PBMC” for short, provide a useful in vitro research tool for various aspects of pathology and biology. PBMC are important for studies in immunology, infectious disease, blood cancers, vaccine development, cell therapy & transplantation, defense mechanisms, bacterial and viral infections, and as an immune surveillance network to kill tumor cells.
In addition, newly launched Human Femoral Artery Endothelial Cells (HFAEC) provide scientists with a model to study atherosclerosis. The large femoral artery, located in the thigh, provides the main blood supply to the lower limb and is susceptible to peripheral arterial disease.
CAI's dedication to vascular research is evident.  “Cell Applications got its start in 1994 selling Microvascular Endothelial Cells,” according to Dr. Daniel Schroen, a VP at Cell Applications, Inc. “What began as a single cell type has now blossomed into an extensive bank of numerous vascular, cardiac and blood cells. We’re happy to continue the expansion of this important component of our overall Primary Cell offering.
Press & Media Relations
Daniel Schroen, PhD
VP, Sales & Marketing
(858) 453-0848